Biotium Introduces Novel Antibody Labeling Kits for Rapid and Efficient Labeling of IgM Antibodies

Biotium, a leading provider of innovative life science solutions, is thrilled to announce the release of its latest product, Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits. These groundbreaking kits revolutionize the labeling process for IgM antibodies, enabling researchers to easily obtain high-performance fluorescent IgM conjugates with minimal hands-on time with no purification after labeling.

IgM antibodies offer advantages over IgG antibodies due to their increased avidity. However, traditional methods for conjugation of IgG antibodies are frequently ineffective for optimal labeling of IgM antibodies due to differences in the immunoglobulin structures. Recognizing this roadblock, Biotium has successfully optimized the reaction conditions and developed Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits to address this issue.

With these kits, researchers can now label 25 ug or 100 ug of their IgM antibody in as little as 15-30 minutes, ensuring efficient and rapid experimental workflows. These kits offer unparalleled convenience, with less than 30 seconds of hands-on time required, saving valuable laboratory resources.

Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits are available in a selection of 8 CF® Dyes and FITC. CF® Dyes are Biotium’s next-generation fluorescent dyes designed to provide superior brightness and photostability compared to other commercially available fluorescent dyes.

Features and benefits of the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits

  • Optimized for IgM: Developed to offer high-performance IgM conjugates
  • Quick and easy: Conjugate in as little as 15-30 minutes, no purification required
  • Wide selection: Available in your choice of 8 bright CF® Dye colors and FITC

Biotium

Mouse anti-beta tubulin clone 5H1 (IgM kappa) was labeled with CF®488A using Mix-n-Stain™ IgM labeling, and then was used to stain methanol-fixed HeLa cells at 5 ug/mL (right panel). The conjugate shows comparable staining specificity compared to unlabeled antibody at 1 ug/mL detected using CF®488A Goat Anti-Mouse IgM Mu chain secondary antibody at 2 ug/mL (left panel).

“We are excited to introduce the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits to the scientific community,” says Dr. Lori Roberts, Director of Bioscience at Biotium. “This technology provides a new and simple solution to the longstanding challenge of IgM conjugation. We believe these kits will provide researchers with more flexibility in panel design for immunofluorescence and flow cytometry.”

For more information about the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits, please visit the product page.

Biotium also offers a range of other labeling solutions to meet diverse research needs. The Mix-n-Stain™ CF® Dye Antibody Labeling Kits are ideal for rapid and efficient labeling of IgG antibodies, while the Mix-n-Stain™ Nanobody Labeling Kits cater to the labeling of single-domain Nanobodies®. Biotium also provides Mix-n-Stain™ kits for labeling antibodies with biotin, DNP, or DIG. Browse Biotium’s full catalog of Mix-n-stain™ Antibody Labeling Kits.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”